Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Acquisitions & Divestments (2023 - 2025)

Kura Oncology (KURA) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $177.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 21.58% to $177.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $755.1 million, a 35.34% increase, with the full-year FY2025 number at $755.1 million, up 35.34% from a year prior.
  • Change in Acquisitions & Divestments was $177.5 million for Q4 2025 at Kura Oncology, down from $235.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $235.0 million in Q3 2025 to a low of $85.0 million in Q1 2023.
  • A 3-year average of $144.9 million and a median of $144.0 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 119.33% in 2024, then decreased 14.57% in 2025.
  • Kura Oncology's Change in Acquisitions & Divestments stood at $141.9 million in 2023, then rose by 2.89% to $146.0 million in 2024, then increased by 21.58% to $177.5 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Change in Acquisitions & Divestments are $177.5 million (Q4 2025), $235.0 million (Q3 2025), and $175.0 million (Q2 2025).